CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER
The present disclosure provides a method for treating alcohol use disorder (AUD) and associated symptoms to a subject in need thereof by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable salt comprises a cyclobenzaprine acid salt.
1 . A method for treating alcohol use disorder (AUD) and associated symptoms, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
2 . The method of claim 1 , wherein the pharmaceutical composition is administered one or more times daily.
3 . The method of claim 2 , wherein the pharmaceutical composition comprises between 0.1 mg and 30 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
4 . The method of claim 2 , wherein the pharmaceutical composition comprises between 1 mg and 20 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
5 . The method of claim 2 , wherein the pharmaceutical composition comprises less than 10 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
6 . The method of claim 2 , wherein the pharmaceutical composition comprises less than 5 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
7 . The method of claim 2 , wherein the pharmaceutical composition comprises about 5.6 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
8 . The method of claim 2 , wherein the pharmaceutical composition comprises about 2.8 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
9 . The method of claim 7 , wherein the pharmaceutical composition is administered as two dosage units, and wherein each dosage unit comprises 2.8 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
10 . The method of claim 7 , wherein the pharmaceutical composition is administered simultaneously as two dosage units, and wherein the combined amount in the two dosage units is 5.6 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
11 . The method of claim 1 , wherein the pharmaceutical composition is administered once daily.
12 . The method of claim 1 , wherein the pharmaceutical composition is administered sublingually, buccally, orally, intravenously, intramuscularly, subcutaneously, inhalationally, intranasally, transdermally, parenterally, rectally, or vaginally.
13 . The method of claim 11 , wherein the pharmaceutical composition is administered for transmucosal absorption.
14 . The method of claim 11 , wherein the pharmaceutical composition is administered sublingually.
15 . The method of claim 12 , wherein the pharmaceutically acceptable salt comprises a cyclobenzaprine acid salt and the pharmaceutical composition further comprises a basifying agent.
16 . The method of claim 15 , wherein the cyclobenzaprine acid salt is cyclobenzaprine HCl.
17 . The method of claim 1 , wherein the cyclobenzaprine or the pharmaceutically acceptable salt thereof in the pharmaceutical composition comprises at least in part a eutectic of cyclobenzaprine or a pharmaceutically acceptable salt thereof and mannitol.
18 . The method of claim 1 , wherein the pharmaceutical composition is administered in combination with behavioral or environmental intervention.
19 . The method of claim 1 , wherein the pharmaceutical composition is administered before, during, or after detoxification.